论文部分内容阅读
目的 观察阿魏酸哌嗪分散片联合氯吡格雷治疗冠心病的疗效.方法 选择本院2015年至2016年收治的88例冠心病患者作为研究对象,按随机数表法将患者分为对照组和试验组,每组44例.对照组予以氯吡格雷治疗,于术前接受氯吡格雷75mg,qd,持续治疗6个月;在对照组基础上,试验组予以阿魏酸哌嗪分散片治疗,口服阿魏酸哌嗪分散片100 mg,tid,持续治疗1个月.比较2组的临床疗效和血清同型半胱氨酸(HCY)、超敏C反应蛋白(HsCRP)、髓过氧化物酶(MPO)、缺血修饰清蛋白(IMA)水平,并观察药物不良反应(ADR)发生情况.结果 试验组和对照组总有效率分别为90.90％(40例/44例)和72.72％(32例/44例),组间比较差异有统计学意义(P＜0.05).治疗后,试验组和对照组的血清HCY分别为(12.48±1.91),(16.36±2.02) μmol·L-;这2组的HsCRP分别为(1.34±0.17),(3.82±0.56)mg·L-1;这2组的MPO分别为(17.36±2.88),(23.26±4.26) mmol·L-1;这2组的IMA分别为(20.10±2.44),(24.91±3.53) μg·L-1,组间比较差异均有统计学意义(均P＜0.05).试验组和对照组的ADR发生率分别为25.00％(11例/44例),20.45％(9例/44例),组间比较差异无统计学意义(P＞0.05).结论 阿魏酸哌嗪分散片联合氯吡格雷治疗冠心病的疗效优于单用氯吡格雷,能够降低血清HCY、HsCRP、MPO、IMA水平,减缓病情.“,”Objective To research the effect of piperazine ferulate dispersed tablets joint clopidogrel in the treatment of coronary heart disease.Methods Patients with coronary heart disease was from January 2015 to December 2016 as the study subjects,according to random number table method they were divided into control group and treatment group,44cases in each group.Control group was treated with clopidogrel,preoperative acceptance of 75 mg clopidogrel,qd,and continuous treatment for 6 months.Treatment group was treated with piperazine ferulate dispersed tablets based on the control group,oral 100 mg of piperazine ferulate dispersed tablets,tid,continuous treatment for 1 month.Clinical effects,serum homocysteine (HCY),hypersensitive C-reactive protein (HsCRP),myeloperoxidase (MPO),ischemia modified albumin (IMA),and adverse drugs reactions(ADR) between two group was compared.Results Total effective rate of the treatment group and control group respectively were 90.90％ (40 cases/44 cases) and 72.72％ (32 cases/44 cases),the difference between groups was significant (P ＜ 0.05).After treatment,the serum HCY in treatment group and control group respectively were (12.48 ± 1.91) and (16.36 ±2.02) μmol · L-1;HsCRP in the two groups respectively were (1.34 ±0.17) and (3.82 ±0.56)mg · L-1,MPO in the two groups respectively were (17.36 ±2.88) and (23.26 ±4.26)mmol · L-1,IMA in the two groups respectively were (20.10 ± 2.44) and (24.91 ± 3.53) μg · L-1,the difference of above factors between groups was significantly (all P ＜ 0.05).Incidence of ADR in treatment group and control group respectively were 25.00％ (11 cases/44 cases) and 20.45％ (9 cases/44 cases),there was no significant difference (P ＞0.05).Conclusion Effect of piperazine ferulate dispersed tablets joint clopidogrel in the treatment of coronary heart disease is better than clopidogrel alone,which reduced serum HCY,HsCRP,MPO and IMA and slowed down the disease.